Seoul, Korea – February 13, 2025 – (SeaPRwire) – The GobizKOREA Online Exhibition is officially underway, bringing together innovative and competitive products from Korean small and medium-sized enterprises for a global business showcase. This dynamic online event, powered by the GobizKOREA global B2B platform, eliminates time and location barriers, enabling real-time interaction and efficient connections between exhibitors and buyers, as Korea’s latest trendy products make their grand debut on the international stage. This online exhibition aims to introduce innovative and competitive products from Korean small and medium-sized suppliers to the global market and strengthen business networks. Based on GobizKOREA’s online platform, this exhibition showcases products from various industries including health and beauty, agriculture and food, clothing and accessories. Additionally, it has significantly enhanced accessibility between global buyers and Korean companies by providing an environment where anyone can participate anytime, without time or location constraints. Participating companies are strengthening their credibility by sharing detailed company and product information, along with various certifications to increase the chance of securing deals with buyers. Buyers interested in trading can access the GobizKOREA website (https://www.gobizkorea.com), browse the various showcased products, and submit purchase inquiries for products of interest. Considering the nature of this non-face-to-face online exhibition, GobizKOREA is actively supporting smooth communication between participating companies and buyers through trade experts, aiming to facilitate practical business cooperation. GobizKOREA is a global B2B platform initiated in 1996 by The Korea SMEs & Startups Agency (KOSME), a government agency of the Republic of Korea. It plays a pivotal role in introducing outstanding products from Korean small and medium-sized suppliers to overseas markets through online channels and supporting global business. Looking for trendy new products with immediate sales potential in the market? Please participate in this online exhibition and directly explore the products. Don’t miss out on valuable business opportunities. Media contact Brand: GobizKOREA Contact: Ru Jieun E-mail: ruji@Gobizkorea.com Website: https://gobizkorea.com Phone: +82-70-4771-1751

Taipei – February 13, 2025 – Ergothioneine, known for their exceptional nutritional value, have been gaining significant global attention as a key ingredient in dietary supplements. According to market data, the global Ergothioneine supplement market is projected to reach USD 34.3 billion in 2024 and grow to USD 47.2 billion by 2028, highlighting vast consumer demand and market potential. Taiwan-based dietary supplement contract manufacturer Welbloom Bio-Tech has over 25 years of experience, offering clients a one-stop professional service. (Photo source: Welbloom Bio-Tech Empowering Brands from Production to Sustainability Welbloom Bio-Tech, a leading Taiwanese contract development and manufacturing organization (CDMO) specializing in dietary supplements, is set to exhibit at the upcoming Natural Products Expo West (NPEW) in March. The company will unveil two innovative products—Wel-EGT® and Wel-Revive®—addressing the evolving health and wellness trends. Founded in 1999, Welbloom Bio-Tech comprises a team of professionals with backgrounds in pharmaceuticals, food science, and nutrition. The company operates an NSF-certified manufacturing facility, offering tailored solutions across the entire product lifecycle, from formulation development and production to training and education. Welbloom Bio-Tech takes pride in its proprietary FRESH-Jelly® technology, an industry-first patented delivery format. The company’s commitment to sustainability is further demonstrated through its newly established LEED Silver-certified facility, which emphasizes the use of local ingredients and eco-friendly packaging while achieving carbon reduction goals. Welbloom Showcasing New Exosome Technology The company’s flagship product, Wel-EGT®, leverages a proprietary mushroom Exosomes extraction technology enriched with amino acids, providing rapid nutrient absorption and boasting a remarkable 92% free radical scavenging rate per milliliter. In response to the aging population trend, Welbloom Bio-Tech will also unveil Wel-Revive®, a powerful anti-aging supplement formulated with turmeric, onion, and strawberry extracts. This compound formula is designed to combat oxidative stress and cellular aging, delivering noticeable results within just four weeks of use. NPEW will take place from March 5 to March 7 in Anaheim, California, where Welbloom Bio-Tech will exhibit at Hall D, Booth #3367. Industry professionals interested in exploring the latest innovations, especially the application of Exosomes in ingredients and formulations, are welcome to visit the booth or contact Jenny Zhu at service@welbloom.com.tw for further inquiries and collaboration opportunities. Media Contact Jenny Zhu service@welbloom.com.tw

Hongkong – February 11, 2025 – (SeaPRwire) – On Feb. 9, 2025, the official website of the Center for Drug Evaluation, National Medical Products Administration of China indicates that the Biologics License Application (BLA) for Luzhu Biotech’s (2480.HK) biological product for prophylaxis, Recombinant Herpes Zoster Vaccine (CHO Cells), has been accepted. This vaccine is the second recombinant herpes zoster vaccine worldwide—following GSK’s Shingrix—and the first of its kind to be submitted for market approval in China. Translated version Origin version 01 How Big Is the Herpes Zoster Vaccine Market? BCHT’s Ganwei is currently the only domestically marketed herpes zoster vaccine in China. Since its launch in 2023, it has generated nearly RMB900 million in sales within the year, drawing significant market attention and rapidly intensifying competition in the field. As of Dec. 31, 2024, over 20 companies in China have advanced their herpes zoster vaccine pipelines into clinical trials or received Investigational New Drug (IND) approvals—an increase from just 4 companies in 2022. In 2023, Zhifei Biological began distributing vaccine Shingrix in China imported from GSK. Shingrix was approved for the Chinese market in less than 3 months through the “Green Channel” in 2019 and was commercialized the following year. As a blockbuster vaccine, Shingrix achieved approximately USD4.2 billion in global sales in 2024, ranking third worldwide. Ganwei and Shingrix represent two distinct technological approaches to herpes zoster vaccines, each with clear advantages and disadvantages. However, do their respective shortcomings in protection efficacy and side effects limit their broader market adoption? Could a new vaccine that combines the strengths of both while addressing their weakness further expand the herpes zoster vaccine market? If approved, Luzhu Biotech’s innovative Recombinant Herpes Zoster Vaccine could potentially be the breakthrough product that achieves this goal. 02 Luzhu Biotech’s Path to Innovation in Herpes Zoster Vaccines Founded in 2001, Luzhu Biotech has been one of China’s leading innovators in vaccine development since its establishment. Before 2008, the company successfully developed three types of bacterial polysaccharide conjugate vaccines and two multivalent meningococcal polysaccharide vaccines, including but not limited to the world’s first AC-Hib conjugate vaccine, the liquid AC polysaccharide conjugate vaccine, and China’s first group ACYW135 meningococcal polysaccharide vaccine. As Luzhu Biotech’s most advanced vaccine project, the company initiated the development of its recombinant herpes zoster vaccine in 2018. After 7 years of research, it has now reached the regulatory submission stage. Globally, only four herpes zoster vaccines are currently on the market—aside from Shingrix, the other three are live-attenuated vaccines. Following the same recombinant protein technology pathway, Luzhu Biotech’s herpes zoster vaccine has undergone rigorous head-to-head comparisons with Shingrix in preclinical studies and Phases 1 and 3 clinical trials. According to publicly disclosed data, Luzhu Biotech’s vaccine has demonstrated superior cellular immune response and a more favorable safety profile compared to Shingrix. Can this vaccine help Luzhu Biotech, a Hong Hong-listed Chapter 18A company, turn profitable and bring substantial revenue? Could it even become a globally recognized blockbuster? Notably, Luzhu Biotech’s herpes zoster vaccine is also undergoing clinical trials in the United States, making it the first Chinese vaccine to be submitted for approval in both China and the United States. If it surpasses Shingrix in overall effectiveness, including protection and safety, it could emerge as the best-in-class product, naturally paving the way for its success in the global market. Whether Luzhu Biotech can inject new vitality into the global vaccine market remains an exciting prospect to watch. PEANUT MEDIA LIMITED Ms. Chen Direct Line: +86-755-61619798 x8210 Email: hswh.project@czgmcn.com http://peanutmedia.com/